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Abstract
Background: Mitral valve repair is favored over replacement due to superior outcomes. However, extensive
infective endocarditis (IE) often has been considered unreconstructable. We retrospectively analyzed the mid-term
outcomes of an individualized repair approach using a lifting annuloplasty strip.
Methods: Between December 2007 and March 2014, 27 consecutive patients with acute single mitral valve IE
(age 43 ± 16 years, 11 men) underwent lifting mitral annuloplasty (LMA) with a strip (Mitracon® strip, 28 mm in 4,
32 mm in 10, and 34 mm in 13). Blood culture was positive in 70 % (Streptococcus 10, Staphylococcus 4, HACEK 3,
Enterococcus 1, Gram negative bacilli 1). One case (4 %) had a previously repaired mitral valve—the repair was
redone. Via right thoracotomy (74 %) or median sternotomy (26 %), repair was performed by removal of vegetation
and resection of infected tissue, the defect typically then being repaired using a bovine pericardial patch (81 %).
Artificial chordae were formed in 5 patients. Nine (33 %) of them had posterior leaflet augmentation (PLA) to get
sufficient coaptation height. Clinical and echocardiographic follow-up were performed.
Results: Compared with preoperative ones, postoperative echocardiograms revealed decreases of left ventricular
(LV) end-diastolic dimensions (57.2 ± 6.3 versus, 45.4 ± 6.2, or 44.8 ± 4.1 mm, all p < 0.01). The LV ejection fraction
decreased immediately, but recovered (64.4 ± 9.6 % vs. 54.5 ± 9.8 %, or 65.2 ± 6.1 %, p = 0.002, p = 1.000, respectively).
The latest follow-up echocardiograms (median 28 months) universally showed no or minimal regurgitation, with a
preserved mitral valve opening area (2.27 ± 0.48 cm2). During the clinical follow-up (median, 54 months), one (3.7 %)
death was observed (in-hospital, due to biliary sepsis and pneumonia). There was no reoperation or major
cardiovascular event. The 5 year survival rate was 96.3 %.
Conclusions: The repair technique of LMA and/or PLA in patients with IE achieved good structural and functional
outcomes as well as an excellent 5 year survival rate. An individualized repair approach should be recommended in
patients with acute phase IE.
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Background
Despite advanced diagnostic modalities and therapeutic
techniques, infective endocarditis (IE) remains a danger-
ous condition with an incidence ranging from 16 to 62
cases per million person-years [1]. Treatment for IE
consists of antibiotic therapy or surgery, or both. Most
patients receive a total of 6 weeks of antibiotics therapy
regardless of the timing of surgery [2]. Indications for
surgical treatment in patients with IE include congestive
heart failure, periannular extension of IE, systemic em-
bolism, cerebrovascular complications, persistent sepsis,
and large vegetations with a risk of embolization [3].
In the setting of degenerative mitral valve regurgita-
tion, mitral valve repair is preferred over mitral valve
replacement, but for treatment of mitral regurgitation
due to IE, mitral valve replacement is preferred because
of concerns about the durability of mitral valve repair,
recurrence of IE, and mitral regurgitation [4–7]. But
recent published clinical trials have suggested that mitral
valve repair may be feasible and offer better survival
compared with mitral valve replacement even in patients
undergoing surgery for IE [1, 8, 9].
The aim of the present single-center, consecutive patient
study is to investigate the outcomes of mitral valve repair
using lifting mitral annuloplasty (LMA) during acute
phase IE having extensive destruction of the mitral valve.
Methods
Study population
The Konkuk University Medical Center Institutional
Review Board approved this retrospective study and
waived the need for individual patient consent. The clin-
ical records of patients who underwent mitral valve
surgery for IE were reviewed from December 2007 to
March 2014. A total 39 mitral valve open heart surgeries
were performed during the study period for correction of
acute phase IE in the mitral valve. Among them, there
were 29 single mitral valve surgeries, the rest double valve,
including the aortic valve. Of the 29 cases, two patients
underwent mitral valve replacement—one underwent
prior open heart surgery for mitral valve replacement and
MAZE for rheumatic mitral valve stenosis and atrial
fibrillation, the other underwent mitral valve repair for
unknown etiology elsewhere. The study cohort of single
mitral valve repairs due to acute phase IE therefore
comprised 27 consecutive patients. The mean age was
43 ± 16 years (range, 21–81), the baseline characteristics
are summarized in Table 1.
Acute phase endocarditis was clinically diagnosed by the
modified Duke criteria [10], and surgically confirmed in
the entire study population. Nineteen patients (70 %) were
blood culture-positive IE. The most common micro-
organisms were Streptococcus in 11 patients (58 %)—
Streptococcus mitis in 4, Streptococcus sanguinis in 2, Other
Viridans streptococci in 2, Streptococcus pneumoniae in 1,
Streptococcus gordonii in 1, and Enterococcus faecalis in 1.
Next were Staphylococcus in 4 (21 %) (Methicillin-resistant
Staphylococcus aureus [MRSA] in 3, and Methicillin-sensitive
Staphylococcus aureus in 1), the Haemophilus parainfluenza
in 3 (16 %), and other gram-negative bacilli in 1 (5 %).
Culture-negative endocarditis was defined as endocarditis in
which no microorganism could be identified either on serial
blood culture or in cultures made from the explanted valvu-
lar tissue of patients presenting with the clinical picture of
endocarditis. Its presentation was significant with systemic
embolism in 12 patients (44 %): embolic stroke was the first
Table 1 Preoperative characteristics of the 27 patients who
underwent lifting mitral annuloplasty
Variables No. (%)
Age (years) 43 ± 16
Male 11 (41)
Indication for surgery (≥ moderate to severe MR) and,
Systemic embolism with large vegetations 12 (44)
Heart failure with acute pulmonary edema 7 (26)
Septic shock 3 (11)
Persistent fever and positive blood cultures
> 7 to 10 days
1 (4)
LV EF (%) 64.4 ± 9.6
MR ERO (cm2) 0.59 ± 0.30












Gram negative bacilli 1
Valvular pathology




Unclear, destructed by vegetations 3
Status post mitral valve repair, elsewhere 1 (4)
MR Mitral regurgitation, LV EF Left ventricular ejection fraction, ERO Effective
regurgitant orifice, MRSA Methicillin- resistant Staphylococcus aureus, MSSA
Methicillin-sensitive Staphylococcus aureus, HACEK Haemophilus, Aggregatibacter,
Cardiobacterium, Eikenella, and Kingella
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presentation in 9 patients, and there were other combined
systemic embolic infarctions in the spleen (2 patients), kidney
(one patient), or other peripheral extremities (2 patients).
The presentation with acute heart failure with acute pulmon-
ary edema was 26 % and with septic shock, 11 %. The
preoperative chest X-ray revealed pulmonary edema in 7
patients while electrocardiograms showed atrial fibrillation in
3 patients (paroxysmal atrial fibrillation in 1).
The preoperative echocardiogram showed a mean left
ventricular (LV) ejection fraction (EF) of 64.4 ± 9.6 %
(range, 35–79 %). One patient had prior mitral valve ring
annuloplasty elsewhere, and the others showed native mi-
tral valves with leaflet prolapse or chordae rupture, and
suspicious underlying rheumatic pathologies (4 patients).
The mitral vegetations were extensive in both anterior
and posterior leaflets in 15 patients, mainly anterior in 9
patients, and posterior in 3 patients. The amount of mitral
valve regurgitation was moderate or severe with an effect-
ive regurgitant orifice (ERO) of 0.59 ± 0.30 cm2 by the
proximal isovelocity surface area method [11].
Timing of surgery
The timing for surgery varied. The median period from
admission to operation was 4 days (interquartile range,
1– 9). As a referral center, the actual interval from diag-
nosis to operation was 20.9 ± 14.0 days, and according to
the culture-driven antimicrobial therapy [12] preopera-
tive intravenous antibiotics were prescribed for 21.0 ±
13.6 days.
Operative procedure
Right anterolateral thoracotomy, as a standard approach
of surgery for mitral valve regurgitation in our center,
was performed in 74 % (20/27) of patients. Under gen-
eral anesthesia with double-lumen intubation, patients
were positioned in left decubitus. Cardiopulmonary by-
pass was initiated using peripheral cannulation through
the right internal jugular vein, right femoral vein, and
right femoral artery, under transesophageal echocardiog-
raphy guidance. Median sternotomy was performed in
26 % (7/27) of patients who had obstructive or restrictive
lung disease on the pulmonary function test (such as
measuring forced expiratory volume in less than 1 s) or
who underwent cardiac surgery via right thoracotomy
previously. All operations were performed using a stand-
ard cardiopulmonary bypass with crystalloid cardioplegia
and mild hypothermia. Operative data are summarized
in Table 2.
All mitral valve repairs were performed through the
left atrium via the groove of Sondergaard. All the visible
vegetations and infected tissues were eliminated. In 22
patients (81 %), including the 3 patients with a previous
perforation from destructive IE, the ruptured hole in
mitral valve leaflets formed by the removal of vegetation
or slicing of the leaflet was repaired with bovine pericar-
dium (Supple Peri-guard® bovine pericardium repair
patch, 6 cm × 8 cm, Synovis® Surgical, Jisang Inter-
national, Inc.). Chordal replacement with expanded poly-
tetrafluoroethylene sutures was performed in 5 (19 %)
patients, posterior leaflet augmentation (PLA) in 9
(33 %) [13]. As the final step, in all patients, LMA was
performed using a mitral strip (Mitracon®, ScienCity Co.,
Seoul, Korea), flat and flexible polyethylene terephthalate,
5 mm wide with two thick margins and a thin gully
between them [14]. The LMA technique was described in
in detail previously [14]. Interrupted mattress sutures of
non-absorbable multifilament material are placed in the
posterior mitral annulus, beginning at the anterolateral
commissure to posteromedial commissure. Six sutures are
generally required. The difference from typical annular
sutures is the placement: in LMA, annular sutures pass
through the left atrial (LA) wall above the posterior mitral
annulus, going slightly through the annulus and then out
through LA wall. This type of suture has the effect of
lifting the posterior annulus to the LA side. Since 2007,
our institution has performed this type of annular suture.
In 9 (33 %) patients, to achieve a sufficient coaptation
length (≥5 mm) to prevent development of mitral regurgi-
tation, PLA was performed using an elliptical pericardial
patch [15]. Other concomitant cardiac procedures were
performed in 4 patients (15 %), including the maze pro-
cedure, tricuspid annuloplasty, and the direct closure of
patent foramen ovale.
Table 2 Operative data
Variables No. (%)
Approach
Right thoracotomy 20 (74)
Left thoracotomy 7 (26)
Repair techniques
Lifting annuloplasty with a strip 27 (100)
Leaflet patching repair 22 (81)
Posterior leaflet augmentation 9 (33)
Artificial chordae formation 5 (19)
Lifting annuloplasty strip size
28 mm 4 (15)
32 mm 10 (37)
34 mm 13 (48)
Concomitant procedure 4 (15)
Cox-Maze procedure 2
Tricuspid annuloplasty 1
Direct closure of persistent foramen ovale 1
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Post-operative antibiotic therapy
In patients with a positive operative tissue culture (two
cases, MRSA, Enterococcus faecalis), full coverage of
antimicrobial therapy was given, starting from the time
of surgery; however, in most patients with a negative
operative tissue culture, the duration of antimicrobial
therapy was calculated from the preoperative antibiotics
for 4 to 6 weeks, and minimum one week of post-
operative period even if the duration extended the over-
all course. The duration of postoperative antibiotic
therapy was 22.4 ± 11.1 days.
Statistical analysis
Statistical analysis was performed with dBSTAT (DB
STAT Version 5. Chuncheon, Korea: DBSTAT Co.; 2010.
http://dbstat.com). Baseline and follow-up data were
expressed as mean (standard deviation) or median
(interquartile range) for continuous variables and as a
number (percentage) for categorical or binary variables.
All continuous data were tested for a normal distribu-
tion using Kolmogorov-Smirnov nonparametric tests.
Sphericity was tested using Mauchly’s test. Serial echo-
cardiographic changes were assessed using a repeated
measures analysis of variance. Post hoc analyses were
performed using Bonferroni’s method. The cumulative
event-free survival curve was determined according to
the Kaplan-Meier method. Two-sided p values < 0.05
were considered statistically significant.
Results
General outcomes
The median postoperative follow-up duration was 54.1
months. The overall mortality rate was 3.7 % (1 of 27): a
72-year-old woman died from septic shock caused by
cholangitis, pancreatitis, and pneumonia, and had a pre-
existing diagnosis of stomach cancer—despite good
immediate-postoperative cardiac function. None of the
patients experienced valve-related complications such as
thromboembolism bleeding events associated anticoagu-
lation. During the follow-up, there was no recurrence of
endocarditis and no reoperation. The 5 year survival rate
was 96.3 %.
Immediate-postoperative echocardiographic results
Comprehensive transthoracic echocardiography was per-
formed before patient discharge, the mean postoperative
period being 7.4 ± 2.4 days. Immediately postoperatively,
all patients showed mitral regurgitation less than grade
1. The LV end-diastolic dimension (EDD) and LV end-
systolic dimension (ESD) decreased from 57.2 ± 6.3 to
45.4 ± 6.2 mm (p < 0.001) and from 35.7 ± 6.7 to 32.5 ±
6.3 mm (p = 0.046),respectively. But the LV EF decreased
from 64.4 ± 9.6 % to 54.5 ± 9.8 % (p = 0.002). The LA
dimension and estimated pulmonary artery systolic
pressure (PASP) also significantly decreased from 46.5 ±
5.9 to 34.4 ± 8.9 mm (p < 0.001) and from 37.1 ± 14.9 to
24.5 ± 6.9 mm Hg (p < 0.001), respectively.
Last-follow-up echocardiographic results
The mean last-follow-up echocardiography interval was
30 ± 22 months. All of the survivors (26 of total 27) in
our series had trivial or mild mitral regurgitation at their
last follow-up visit. Follow-up LV reversal remodeling
measured by the change in LV EDD, ESD, and EF was
observed after surgery. The LV EDD and ESD decreased
significantly compared with preoperative findings, from
57.2 ± 6.3 to 44.8 ± 4.1 mm (p < 0.001) and 35.7 ±
6.7 mm to 28.3 ± 2.9 mm (p < 0.001). The decreased LV
EF in the immediate postoperative period improved
from 54.5 ± 9.8 % to 65.2 ± 6.1 % (Fig. 1). The LA dimen-
sion and estimated PASP persistently decreased from
46.5 ± 5.9 to 35.3 ± 9.6 mm (p < 0.001) and 37.1 ± 14.9 to
26.9 ± 5.1 mmHg (p = 0.012). The mean mitral valve area
measured by two-dimensional area was 2.27 ± 0.48 cm2
at the last follow-up visit. The echocardiographic find-
ings are summarized in Table 3 and Fig. 1.
Discussion
Mitral valve repair is a standard treatment for nonin-
fected valvular disease. One of the advantages of mitral
valve repair over mitral valve replacement is the preser-
vation of LV function. Kouris and associates reported
that mitral valve repair in patients with mitral regurgitation
achieved better preservation of LV systolic indices than
mitral valve replacement, probably due to preservation of
the subvalvular apparatus and LV geometry [16], and
several studies have suggested better survival and freedom
from anticoagulant related hemorrhage, thromboembol-
ism, and endocarditis [17, 18]. For these reasons, mitral
valve repair is preferred to valve replacement in patients
with degenerative mitral valve disease. Already the use of
mitral valve repair has exceeded the use of replacement.
Gammie et al. demonstrated that the rate of mitral valve
repair versus replacement increased from 51 to 69 % and
that operative risks of mitral valve repair were significantly
lower than those for mitral valve replacement [19]. Barnett
et al. reported that the surgical treatment for mitral disease
has transitioned to primarily one of repair, not replacement
[20]. But valvular replacement has been performed only
infrequently for patients with mitral valve endocarditis
because of the fragile valvular apparatus and concerns
about recurrent IE and mitral valve plasty durability.
Gammie et al. reported a 20 and 48 % feasibility rate of
mitral valve repair in active and healed endocarditis
respectively [8].
The most recent reports suggest acceptable short- and
long-term outcomes. Ruttmann et al. demonstrated that
event-free survival at 1 year was 88.2 and 80.4 % at
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5 years in the repair group [4]. Miura et al. reported that
4-year survival was 88.2 % and the 4-year reoperation-
free rate was 92.4 % in the repair group [21]. Shimokawa et
al. reported that freedom from moderate or severe MR was
91.9 % ± 1.5 % and 83.3 % ± 2.3 % at 10 years [5]. Zegdi et
al. reported that the 10-year survival rate and freedom
from mitral valve reoperation were 80 and 91 %, respect-
ively [7]. In our series, the overall mortality rate was 3.7 %
(1 of 27) and the 5 year survival rate was 96.3 %.
In active endocarditis, the feasibility of valve repair
depends on the extent of the pathological lesion [22]. In
published studies, the feasibility of repairing infected mi-
tral valves for acute endocarditis has been demonstrated
to vary from 33 to 78 % [1]. Iung et al. reported that MV
repair was feasible in 81 % of patients; 19 % of patients
underwent MVR because of the extent of tissue destruc-
tion [23]. In our study, among the consecutive patients
who underwent open heart surgery due to single mitral
valve IE, only two patients (2 of 29) had replacements,
both of them re-doing prior mitral valve operations. The
extent of pathological lesions seemed not to restrict the
choice for repair over replacement—most (15 of 27) in-
volved both anterior and posterior leaflets, with the clin-
ical and echocardiographic findings showing favorable
outcomes.
Although an important surgical rule when dealing with
valve surgery due to IE is to avoid the use of prosthetic
material as often as possible, in our case, using the LMA
strip with or without bovine pericardium to reconstruct
the mitral valve defect, there was no recurrent endocar-
ditis during the median follow-up of 54 months. The
reported recurrence rates of endocarditis in patients
undergoing mitral valve repair for active endocarditis
were as low as 1 in 37 patients [7]. In our study, we do
not confirm that the mitral strip was tolerant of infec-
tion, but we believe that our novel technique of LMA
with a strip, with or without PLA, helped to increase the
reconstructibility in active endocarditis as to 27 of 29
(93 %), which overall helps reduce the recurrence of
endocarditis in surgically treated active IE. Radical
Fig. 1 Serial changes of echocardiographic parameters: preoperative, median 7 days, and median 30 months after lifting mitral annuloplasty
(T0, T1, and T2, respectively). a Left ventricular end-diastolic dimension (LV EDD, mm); b Left ventricular end-systolic dimension (LV ESD, mm);
c Left ventricular ejection fraction (LV EF, %); d Left atrial dimension (LAD, mm); e Estimated pulmonary arterial systolic pressure (PASP, mm Hg)
from tricuspid regurgitation peak velocity with estimated right atrial pressure. CI, Confidence interval. *P < 0.05, T0 versus T1 and T2, †P < 0.05, T1
versus T2, by post hoc Bonferroni’s test
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debridement of infective tissue followed by local anti-
biotic irrigation and fully maintained intravenous anti-
biotic therapy for 4–6 weeks are, we believe, important
concomitants in preventing recurrence of IE [24].
In patients with rheumatic valve pathology such as
shrunken or thickened leaflets, we sliced the leaflet to
increase pliability and then augmented the posterior
leaflet using bovine pericardium. This technique has
been described by Chauvaud et al. [13]. We used a
bovine pericardium because the use of this material has
been shown to be more cost-effective although no data
are available on the long-term results of the use of
bovine pericardium—longer follow-up is essential.
The normal mitral annulus is not a two-dimensional
flat and fixed structure but rather takes the three-
dimensional form of a saddle [25]. The saddle shape is
accentuated from late diastole to early systole in the
normal annulus but this change is blunted in mitral
valve disease [26]. This shape has been shown to reduce
stress on the mitral leaflet, an important determinant of
durability after mitral valve repair [27]. Our lifting annu-
loplasty was based on this concept. Anatomically, the
anterior mitral annulus attaches to the fibrous skeleton
at the base of the heart and is more rigid; the posterior
annulus is thinner and more susceptible to dilatation
[28]. With LMA, annular sutures go through the LA
wall above the posterior mitral annulus, then slightly go
through the annulus and out through LA wall. This
annular suture technique has the effect of lifting the
posterior annulus to the LA side and increasing the
annulus three-dimensional curvature. In this study, in
patients with active IE, repair of mitral valve using LMA
with or without PLA reveals good outcomes with an
acceptable coaptation of both mitral leaflets.
A decrease in atrial and ventricular size, called reverse
remodeling, has been observed after mitral valve proce-
dures. In our study, the immediate postoperative LV EF
was decreased but recovered after follow-up. This
phenomenon may be because the LV EDD is reduced
more quickly than the LV ESD, resulting in a decreased
LV EF; however, the negative remodeling of the LV ESD
restored the LV EF (Fig. 1). These findings mean that
reverse remodeling may need significant time.
Limitations
This is a single-center experience with a relatively small
number of patents. Our study excluded patients having
mitral valve replacement in order to focus on the effects
of our techniques on mitral valve repair with endocardi-
tis per se, and comparison between mitral valve repair
and replacement was limited due to only 2 patients under-
going replacement. Finally, we are aware that the lack of
comparison with other repair techniques limits conclu-
sions concerning the superiority of the LMA approach.
However, repair techniques using bovine pericardium and
LMA has enabled us to suggest that extensive IE is not a
strong contraindication for mitral valve repair. Further
studies incorporating a larger number of patients and
Table 3 Post-operative echocardiographic findings
Pre-operative Post-operative
Immediately after P value* Last follow-up P value*
Follow-up duration 7.4 ± 2.4 days 30 ± 22 months
MR ERO (cm2) 0.59 ± 0.30
MR grade 3.68 ± 0.50 0.1 ± 0.2 <0.001 0.37 ± 0.22 <0.001
0 ~ I 0 27 26
II 1 0 0
III 4 0 0
IV 22 0 0
MVA, 2D (cm2) 2.27 ± 0.48
LV EF (%) 64.4 ± 9.6 54.5 ± 9.8* 0.002 65.2 ± 6.1** 1.000
LV EDD (mm) 57.2 ± 6.3 45.4 ± 6.2* <0.001 44.8 ± 4.1* <0.001
LV ESD (mm) 35.7 ± 6.7 32.5 ± 6.3* 0.046 28.3 ± 2.9*** <0.001
LAD (mm) 46.5 ± 6.0 35.4 ± 6.3* <0.001 36.6 ± 6.8* <0.001
PASP (mmHg) 37.5 ± 14.2 24.5 ± 6.6* <0.001 26.7 ± 5.0* 0.012
MR mitral regurgitation, ERO effective regurgitant orifice, MVA mitral valve area, 2D two-dimensional, LV left ventricular, EF ejection fraction, EDD end-diastolic
dimension, ESD end-systolic dimension, LAD left atrial dimension, PASP pulmonary artery systolic pressure estimated by tricuspid regurgitation peak velocity with
right atrial pressure
*compared with preoperative
**P < 0.01, immediate after versus last follow-up
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comparable groups using other repair techniques are
necessary to evaluate the relative advantages of our mitral
valve repair techniques.
Conclusion
This repair technique of LMA with or without PLA in
patients with acute-phase IE achieved good structural
and functional outcomes as well as an excellent 5 year
survival rate. An individualized repair approach should
be recommended in patients with acute-phase IE.
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